Advertisement
Canada markets closed

  • S&P/TSX

    22,465.37
    +165.54 (+0.74%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • DOW

    40,003.59
    +134.21 (+0.34%)
     

  • CAD/USD

    0.7348
    +0.0002 (+0.03%)
     

  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     

  • Bitcoin CAD

    91,538.20
    +97.99 (+0.11%)
     

  • CMC Crypto 200

    1,370.19
    -3.65 (-0.27%)
     

  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     

  • RUSSELL 2000

    2,095.72
    -0.53 (-0.03%)
     

  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     

  • NASDAQ

    16,685.97
    -12.35 (-0.07%)
     

  • VOLATILITY

    11.99
    -0.43 (-3.46%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • CAD/EUR

    0.6755
    -0.0001 (-0.01%)
     

Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2 min read

Alkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same period compares to $0.01 a year ago.

The reported revenue represents a surprise of -2.75% over the Zacks Consensus Estimate of $360.26 million. With the consensus EPS estimate being $0.59, the EPS surprise was -25.42%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Manufacturing and Royalty revenues: $116.83 million compared to the $122.54 million average estimate based on six analysts. The reported number represents a change of +60.4% year over year.

  • Revenues- Product sales, net: $233.54 million versus $240.07 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.

  • Revenues- Proprietary Sales- LYBALVI: $57 million versus the four-analyst average estimate of $57.01 million. The reported number represents a year-over-year change of +50%.

  • Revenues- Proprietary Sales- ARISTADA: $78.90 million versus the four-analyst average estimate of $81.37 million. The reported number represents a year-over-year change of -1.5%.

  • Revenues- Proprietary Sales- VIVITROL: $97.70 million versus $98.90 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1% change.

View all Key Company Metrics for Alkermes here>>>

Shares of Alkermes have returned -8.3% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alkermes plc (ALKS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research